Formatech Donates Services to Formulate and Fill Tracon Pharmaceuticals' TRC102 Compound under Its "FillanthropyTM Program"

March 22, 2010

 

ANDOVER, Mass.--Today, Formatech, Inc. announces the selection of Tracon Pharmaceuticals' TRC102 clinical product as the next FillanthropyTM Program candidate. Under this program, Formatech donates the services required to aseptically fill and finish one lot of the drug candidate to support Tracon's upcoming clinical trials.

"TRC102 is a small molecule inhibitor of DNA base excision repair that shows very promising results in animal models and cancer patients when administered in conjunction with chemotherapeutic agents such as Temodar® and Alimta®," said Jeffrey Bernard, Formatech's Director of Business Development. "This compound appears to potentiate chemotherapeutic efficacy as well as prevent drug resistance. We're excited to play a role in the development of this beneficial compound."

"We are pleased to be able to work with Formatech, one of the leaders in the field of drug product formulation and manufacture," said Charles Theuer, Tracon's President and CEO. "We are deeply appreciative that their Fillanthropy Program will allow us to continue our Phase 1 study of TRC102 in combination with Temodar for advanced cancer patients, and to initiate a Phase 2 study of TRC102 in combination with Alimta for patients with lung cancer."

About the Fillanthropy Program

Each month, Formatech will select a company to donate the services required to aseptically fill and finish one lot of drug product entering human clinical trials. We consider both the product's potential therapeutic benefit and the financial need of the applicant. To apply, companies are encouraged to contact Jeffrey Bernard at 978-725-9077 x 3164 or jbernard@formatech.com.

About Formatech

Formatech is a contract service provider that delivers unique solutions to bio/pharmaceutical product development and manufacturing challenges. To learn more about the company and its services, visit www.formatech.com

Formatech's mission is to "Help make new drugs happen at the speed of science."

About Tracon Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. To learn more about the company and its products, visit www.traconpharma.com.

 

BioFlash

Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.